Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities

Radiation Oncology

Table 1 Baseline characteristics of 73 patients with LS-SCLC treated with early CCRT

Variable	Result
Age, median (range), years ≥ 70/ < 70 years	66 (34–77) 19/54
Sex, male/female	55/18
ECOG-PS, 0/1/2	42/28/3
Clinical stage, I/II/III^a	0/15/58
Brinkmann index, ≥ 400/ < 400	71/2
Preexistence of ILAs, yes/no	11/62
V20, median (range), %	24 (13–36) (n = 72)
Number of patients receiving AHF	72
Number of patients receiving PCI	45
Chemotherapy regimen, CDDP/CBDCA	72/1

^aClinical staging according to the 7th edition of the TNM classification of lung cancer [9]. LS-SCLC, limited-stage small-cell lung cancer
CCRT, concurrent chemoradiotherapy; ECOG-PS, Eastern Cooperative Oncology Group performance status; ILA, interstitial lung abnormality; V20, percentage of normal lung receiving at least 20 Gy; AHF, accelerated hyperfractionation; PCI, prophylactic cranial irradiation; CDDP, cisplatin; CBDCA, carboplatin

ISSN: 1748-717X